Sinopharm Group Co Stock Gross Profit
Sinopharm Group Co fundamentals help investors to digest information that contributes to Sinopharm Group's financial success or failures. It also enables traders to predict the movement of Sinopharm Pink Sheet. The fundamental analysis module provides a way to measure Sinopharm Group's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sinopharm Group pink sheet.
Sinopharm |
Sinopharm Group Co Company Gross Profit Analysis
Sinopharm Group's Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Current Sinopharm Group Gross Profit | 44.05 B |
Most of Sinopharm Group's fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sinopharm Group Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
CompetitionAccording to the company disclosure, Sinopharm Group Co reported 44.05 B of gross profit. This is much higher than that of the Healthcare sector and significantly higher than that of the Medical Distribution industry. The gross profit for all United States stocks is 60.9% lower than that of the firm.
Sinopharm Gross Profit Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sinopharm Group's direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Sinopharm Group could also be used in its relative valuation, which is a method of valuing Sinopharm Group by comparing valuation metrics of similar companies.Sinopharm Group is currently under evaluation in gross profit category among its peers.
Sinopharm Fundamentals
Return On Equity | 0.13 | |||
Return On Asset | 0.0364 | |||
Profit Margin | 0.01 % | |||
Operating Margin | 0.04 % | |||
Current Valuation | 16.78 B | |||
Shares Outstanding | 1.34 B | |||
Shares Owned By Insiders | 0.01 % | |||
Shares Owned By Institutions | 51.07 % | |||
Price To Earning | 5.67 X | |||
Price To Book | 0.88 X | |||
Price To Sales | 0.01 X | |||
Revenue | 521.05 B | |||
Gross Profit | 44.05 B | |||
EBITDA | 20.76 B | |||
Net Income | 7.76 B | |||
Cash And Equivalents | 32.15 B | |||
Cash Per Share | 10.30 X | |||
Total Debt | 8.42 B | |||
Debt To Equity | 0.89 % | |||
Current Ratio | 1.31 X | |||
Book Value Per Share | 21.01 X | |||
Cash Flow From Operations | 9.31 B | |||
Earnings Per Share | 0.37 X | |||
Price To Earnings To Growth | 49.02 X | |||
Number Of Employees | 113.23 K | |||
Beta | 0.72 | |||
Market Capitalization | 8.94 B | |||
Total Asset | 335.41 B | |||
Retained Earnings | 11.43 B | |||
Working Capital | 32.26 B | |||
Current Asset | 130.51 B | |||
Current Liabilities | 98.25 B | |||
Z Score | 1.6 | |||
Annual Yield | 0.05 % | |||
Five Year Return | 3.09 % | |||
Net Asset | 335.41 B | |||
Last Dividend Paid | 0.75 |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Other Consideration for investing in Sinopharm Pink Sheet
If you are still planning to invest in Sinopharm Group check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sinopharm Group's history and understand the potential risks before investing.
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |